SG11201704707PA - Compositions and methods for treating and diagnosing chemotherapy-resistant cancers - Google Patents
Compositions and methods for treating and diagnosing chemotherapy-resistant cancersInfo
- Publication number
- SG11201704707PA SG11201704707PA SG11201704707PA SG11201704707PA SG11201704707PA SG 11201704707P A SG11201704707P A SG 11201704707PA SG 11201704707P A SG11201704707P A SG 11201704707PA SG 11201704707P A SG11201704707P A SG 11201704707PA SG 11201704707P A SG11201704707P A SG 11201704707PA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- treating
- methods
- resistant cancers
- chemotherapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462096355P | 2014-12-23 | 2014-12-23 | |
US201562200340P | 2015-08-03 | 2015-08-03 | |
PCT/US2015/067427 WO2016106340A2 (en) | 2014-12-23 | 2015-12-22 | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201704707PA true SG11201704707PA (en) | 2017-07-28 |
Family
ID=55275162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201704707PA SG11201704707PA (en) | 2014-12-23 | 2015-12-22 | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
Country Status (14)
Country | Link |
---|---|
US (1) | US20170253933A1 (en) |
EP (1) | EP3237639A2 (en) |
JP (1) | JP2018508183A (en) |
KR (1) | KR20170094165A (en) |
CN (1) | CN107109491A (en) |
AU (1) | AU2015369624A1 (en) |
BR (1) | BR112017010788A2 (en) |
CA (1) | CA2968359A1 (en) |
HK (1) | HK1243141A1 (en) |
IL (1) | IL252361A0 (en) |
MX (1) | MX2017006864A (en) |
RU (1) | RU2710735C2 (en) |
SG (1) | SG11201704707PA (en) |
WO (1) | WO2016106340A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
EP3576737A4 (en) | 2017-02-06 | 2021-04-21 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
JP7379355B2 (en) | 2017-11-20 | 2023-11-14 | トルレモ セラピューティクス アーゲー | Diagnostic method |
KR102141997B1 (en) | 2017-11-22 | 2020-08-06 | (주)인핸스드바이오 | Biomarker composition for diagnosing radiation resistant cancer or predicting prognosis of radiation therapy comprising PMVK |
WO2019103456A2 (en) * | 2017-11-22 | 2019-05-31 | 울산대학교 산학협력단 | Biomarker composition for diagnosing radiation-resistant cancer or for predicting prognosis of radiation therapy containing pmvk as active ingredient |
EP3775229A4 (en) * | 2018-03-27 | 2021-12-15 | The Trustees Of The University Of Pennsylvania | Modified immune cells having enhanced function and methods for screening for same |
WO2020003213A1 (en) * | 2018-06-27 | 2020-01-02 | Medpacto, Inc. | Methods of diagnosing and treating cancer patients expressing high levels of tgf-b response signature |
EP3874274B1 (en) * | 2018-10-31 | 2024-01-03 | Regents of the University of Minnesota | Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer |
WO2020140927A1 (en) * | 2019-01-02 | 2020-07-09 | Crownmab Biotech Inc. | Cancer treatment using multi-targeted kinase inhibitor in combination of protein kinase biomarkers |
CN110563830B (en) * | 2019-09-16 | 2021-01-29 | 中南大学湘雅医院 | ANXA 1-derived polypeptide and application thereof |
CN110950960B (en) * | 2019-11-26 | 2021-05-14 | 中国农业大学 | Preparation method of small molecule compound antibody based on high-throughput sequencing and hybrid hybridoma technology |
CA3171333A1 (en) * | 2020-02-20 | 2021-08-26 | Versitech Limited | Pd1-based vaccination composition and methods thereof |
CN111440871A (en) * | 2020-04-26 | 2020-07-24 | 至本医疗科技(上海)有限公司 | Application of gene marker in lung cancer prognosis judgment |
RU2738167C1 (en) * | 2020-06-08 | 2020-12-09 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации | Method for determining the effectiveness of chemotherapy with platinum preparations in iii-iv stage ovarian cancer |
WO2022187092A1 (en) * | 2021-03-01 | 2022-09-09 | Genentech, Inc. | Diagnostic methods and methods of treatment of ovarian cancer |
CN113174439B (en) * | 2021-03-30 | 2022-06-28 | 中国医学科学院肿瘤医院 | Application of immune gene pair scoring system in predicting immunotherapy effect of non-small cell lung cancer patient |
KR20230001587A (en) * | 2021-06-28 | 2023-01-05 | 연세대학교 산학협력단 | A pharmaceutical composition for preventing or treating cancer |
CN113876753A (en) * | 2021-10-20 | 2022-01-04 | 复旦大学附属中山医院 | Pharmaceutical application of recombinant human galectin 1 inhibitor |
WO2024054074A1 (en) * | 2022-09-07 | 2024-03-14 | 재단법인 아산사회복지재단 | Pharmaceutical composition for suppressing chemotherapy resistance in solid tumor patient, and use thereof |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (en) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
JP2975679B2 (en) | 1989-09-08 | 1999-11-10 | ザ・ジョーンズ・ホプキンス・ユニバーシティ | Structural change of EGF receptor gene in human glioma |
US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
CA2134773A1 (en) | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
AU687727B2 (en) | 1992-10-28 | 1998-03-05 | Genentech Inc. | Vascular endothelial cell growth factor antagonists |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
ES2166368T3 (en) | 1993-12-24 | 2002-04-16 | Merck Patent Gmbh | IMMUNOCONJUGADOS. |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
MX9700535A (en) | 1994-07-21 | 1997-04-30 | Akzo Nobel Nv | Cyclic ketone peroxide formulations. |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
DE69522717T2 (en) | 1995-03-30 | 2002-02-14 | Pfizer | quinazoline derivatives |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
WO1996040210A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
SK398A3 (en) | 1995-07-06 | 1998-07-08 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GEP20012442B (en) | 1996-04-12 | 2001-05-25 | Warner Lambert Co | Irreversible Inhibitors of Tyrosine Kinases |
ES2186908T3 (en) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | HETEROCICICLES CONDENSED COMPOUNDS AS INHIBITORS OF PPROTEINA-TIROSINA-QUINASAS. |
ID18494A (en) | 1996-10-02 | 1998-04-16 | Novartis Ag | PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT |
UA73073C2 (en) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Substituted 3-cyan chinolines |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
EP1787999B1 (en) | 1997-04-07 | 2010-08-04 | Genentech, Inc. | Anti-VEGF antibodies |
DK0971959T3 (en) | 1997-04-07 | 2006-05-15 | Genentech Inc | Humanized antibodies and methods for producing humanized antibodies |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
CA2288705C (en) | 1997-05-06 | 2008-03-18 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
CN1278176A (en) | 1997-11-06 | 2000-12-27 | 美国氰胺公司 | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
CZ20011759A3 (en) | 1998-11-19 | 2002-01-16 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, irreversible inhibitor of tyrosine kinases |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
EP1492568A1 (en) | 2002-04-08 | 2005-01-05 | SmithKline Beecham Corporation | Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor |
BRPI0411200A (en) | 2003-05-30 | 2006-07-18 | Genentech Inc | cancer treatment method, human patient treatment methods, industrialized article and cancer treatment kit |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
WO2008098086A2 (en) * | 2007-02-06 | 2008-08-14 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | A gene expression profile that predicts ovarian cancer subject response to chemotherapy |
WO2009074968A2 (en) * | 2007-12-12 | 2009-06-18 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for predicting the efficacy of cancer therapy |
WO2011153345A2 (en) * | 2010-06-03 | 2011-12-08 | Beth Israel Deaconess Medical Center, Inc. | A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients |
BR122020012255B1 (en) | 2010-12-16 | 2022-08-09 | Genentech, Inc | USE OF AN ANTI-IL-13 ANTIBODY, USES OF A TH2 PATHWAY INHIBITOR AND ANTI-PERIOSTIN ANTIBODIES |
RU2666627C2 (en) * | 2012-03-30 | 2018-09-11 | Дженентек, Инк. | Methods of diagnosis and composition for cancer treatment |
TW201400810A (en) * | 2012-06-01 | 2014-01-01 | Taiho Pharmaceutical Co Ltd | Chemotherapy selection method for stomach cancer patients |
AU2013331154B2 (en) * | 2012-10-17 | 2018-02-01 | Cedars-Sinai Medical Center | Molecular signatures of ovarian cancer |
CN105102631A (en) * | 2012-12-03 | 2015-11-25 | 阿尔玛克诊断有限公司 | Molecular diagnostic test for cancer |
-
2015
- 2015-12-22 EP EP15831106.8A patent/EP3237639A2/en not_active Withdrawn
- 2015-12-22 RU RU2017125054A patent/RU2710735C2/en active
- 2015-12-22 SG SG11201704707PA patent/SG11201704707PA/en unknown
- 2015-12-22 MX MX2017006864A patent/MX2017006864A/en unknown
- 2015-12-22 CN CN201580070095.7A patent/CN107109491A/en active Pending
- 2015-12-22 WO PCT/US2015/067427 patent/WO2016106340A2/en active Application Filing
- 2015-12-22 AU AU2015369624A patent/AU2015369624A1/en not_active Abandoned
- 2015-12-22 BR BR112017010788A patent/BR112017010788A2/en not_active Application Discontinuation
- 2015-12-22 CA CA2968359A patent/CA2968359A1/en not_active Abandoned
- 2015-12-22 JP JP2017534208A patent/JP2018508183A/en active Pending
- 2015-12-22 KR KR1020177014690A patent/KR20170094165A/en unknown
-
2017
- 2017-05-17 US US15/597,789 patent/US20170253933A1/en not_active Abandoned
- 2017-05-18 IL IL252361A patent/IL252361A0/en unknown
-
2018
- 2018-02-23 HK HK18102602.6A patent/HK1243141A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20170094165A (en) | 2017-08-17 |
AU2015369624A1 (en) | 2017-06-08 |
RU2017125054A3 (en) | 2019-10-23 |
JP2018508183A (en) | 2018-03-29 |
EP3237639A2 (en) | 2017-11-01 |
HK1243141A1 (en) | 2018-07-06 |
CN107109491A (en) | 2017-08-29 |
IL252361A0 (en) | 2017-07-31 |
MX2017006864A (en) | 2017-08-28 |
US20170253933A1 (en) | 2017-09-07 |
WO2016106340A2 (en) | 2016-06-30 |
RU2710735C2 (en) | 2020-01-10 |
RU2017125054A (en) | 2019-01-24 |
CA2968359A1 (en) | 2016-06-30 |
WO2016106340A3 (en) | 2016-09-01 |
BR112017010788A2 (en) | 2017-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1243141A1 (en) | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers | |
HK1253093A1 (en) | Methods of diagnosing and treating cancer | |
HK1246714A1 (en) | Apparatuses and methods for neuromodulation | |
IL253162A0 (en) | Compositions and methods for treatment and detection of cancers | |
SG11201700079VA (en) | Combination therapy compositions and methods for treating cancers | |
HK1251862A1 (en) | Methods and compositons for treating cancer | |
PL3200815T3 (en) | Methods and compositions for treating cancer | |
GB201420859D0 (en) | Tumour analysis | |
SG11201610551TA (en) | Combinations for treating cancers | |
IL247267A0 (en) | Improved methods for the treatment of vascularizing cancers | |
GB201419132D0 (en) | Radiotherapy apparatus | |
SG11201703191TA (en) | Application testing | |
SG10201913528PA (en) | Methods of diagnosing cancer | |
IL246558A0 (en) | Novel methods for treating cancer | |
EP3154544A4 (en) | Compositions and methods for treating cancers | |
EP3092027A4 (en) | Transpapillary methods and compositions for diagnosing and treating breast conditions | |
HK1231405A1 (en) | Methods and compositions for screening and detecting cancer | |
ZA201703771B (en) | Compositions and methods for treating hyperkalemia | |
GB201417372D0 (en) | Methods and kits | |
GB2522037B (en) | Test arrangement | |
PL3180295T3 (en) | Process for fast humification and biostabilization | |
HUE048870T2 (en) | Testing disk | |
GB2526850B (en) | Logic analyzer | |
GB2527789B (en) | Testing apparatus | |
GB201401806D0 (en) | Novel methods for diagnosis and therapy |